MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
2.000
+0.060 (3.09%)
Sep 5, 2025, 4:00 PM - Market closed
MacroGenics Revenue
MacroGenics had revenue of $22.24M in the quarter ending June 30, 2025, with 105.99% growth. This brings the company's revenue in the last twelve months to $165.50M, up 303.47% year-over-year. In the year 2024, MacroGenics had annual revenue of $149.96M with 155.26% growth.
Revenue (ttm)
$165.50M
Revenue Growth
+303.47%
P/S Ratio
0.76
Revenue / Employee
$485,323
Employees
341
Market Cap
126.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MGNX News
- 4 days ago - MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 23 days ago - MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewsWire
- 24 days ago - MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewsWire
- 3 months ago - MacroGenics: Working On That Road To Recovery - Seeking Alpha
- 3 months ago - MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewsWire
- 3 months ago - MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - MacroGenics Announces Date of First Quarter 2025 Financial Results - GlobeNewsWire